Important Note: The Guardant360 test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity testing. This test has not been cleared or approved by the US FDA.

bTMB, blood-based tumor mutation burden; HRR, homologous recombinational repair; MSI, microsatellite instability; NTRK, neurotropic tyrosine receptor kinase.